Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $419M | $79M | $49M | $73M | 18.9% | 20.0% | 14.5% |
| 2024 | $349M | $65M | $42M | $65M | 22.0% | 8.5% | -27.2% |
| 2023 | $321M | $41M | $58M | $25M | 40.8% | 20.0% | -292.8% |
| 2022 | $268M | $-11M | $-30M | $-19M | 167.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 267.84 | 321.48 | 348.88 | 418.63 |
| Operating Revenue | - | 267.84 | 321.48 | 348.88 | 418.63 |
| Cost Of Revenue | - | 48.32 | 54.63 | 60.07 | 73.01 |
| Gross Profit | - | 219.52 | 266.84 | 288.81 | 345.62 |
| Operating Expense | - | 234.25 | 229.73 | 229.50 | 281.73 |
| Research And Development | - | 12.70 | 12.66 | 12.34 | 15.10 |
| Selling General And Administration | - | 208.67 | 211.12 | 225.09 | 266.19 |
| Total Expenses | - | 282.57 | 284.36 | 289.57 | 354.74 |
| Operating Income | - | -14.73 | 37.12 | 59.31 | 63.89 |
| Total Operating Income As Reported | - | -14.73 | 37.12 | 58.86 | 63.89 |
| EBITDA | - | -10.68 | 40.54 | 65.35 | 78.77 |
| Normalized EBITDA | - | -10.68 | 40.54 | 65.80 | 78.77 |
| EBIT | - | -14.73 | 37.12 | 59.31 | 63.89 |
| Interest Expense | 4.98 | 5.02 | 6.46 | 1.01 | - |
| Net Interest Income | - | -5.02 | -6.46 | -1.01 | 2.93 |
| Other Non Operating Income Expenses | - | 0 | -0.03 | -0.56 | -0.56 |
| Other Income Expense | - | 0 | -0.03 | -1.01 | -0.56 |
| Interest Expense Non Operating | 4.98 | 5.02 | 6.46 | 1.01 | - |
| Net Non Operating Interest Income Expense | - | -5.02 | -6.46 | -1.01 | 2.93 |
| Pretax Income | - | -19.75 | 30.63 | 57.29 | 66.26 |
| Tax Provision | - | 0.21 | -36.81 | 15.30 | 17.68 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | -0.12 | 0 |
| Net Income Continuous Operations | - | -19.95 | 67.44 | 42 | 48.58 |
| Net Income From Continuing And Discontinued Operation | - | -30.20 | 58.23 | 42.42 | 48.58 |
| Net Income From Continuing Operation Net Minority Interest | - | -19.95 | 67.44 | 42 | 48.58 |
| Net Income | - | -30.20 | 58.23 | 42.42 | 48.58 |
| Net Income Common Stockholders | - | -36.78 | 46.58 | 42.42 | 48.58 |
| Net Income Including Noncontrolling Interests | - | -30.20 | 58.23 | 42.42 | 48.58 |
| Normalized Income | - | -19.95 | 67.44 | 42.32 | 48.58 |
| Diluted NI Availto Com Stockholders | - | -36.78 | 46.58 | 42.42 | 48.58 |
| Basic Average Shares | - | 112.91 | 116.50 | 146.98 | 147.79 |
| Diluted Average Shares | - | 112.91 | 145.96 | 149.05 | 149.72 |
| Reconciled Depreciation | - | 4.05 | 3.43 | 6.04 | 14.88 |
| Reconciled Cost Of Revenue | - | 44.97 | 51.97 | 54.80 | 58.57 |
| Total Unusual Items | - | 0 | 0 | -0.45 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | -0.45 | 0 |
| Preferred Stock Dividends | 5.21 | 6.58 | 6.75 | - | - |
| Net Income Discontinuous Operations | - | -10.24 | -9.21 | 0.42 | 0 |
| Special Income Charges | - | 0 | 0 | -0.45 | 0 |
| Impairment Of Capital Assets | - | 0 | 0 | 0.45 | 0 |
| Depreciation Amortization Depletion Income Statement | - | 0.70 | 0.76 | 0.76 | 0.44 |
| Depreciation And Amortization In Income Statement | - | 0.70 | 0.76 | 0.76 | 0.44 |
| Total Other Finance Cost | - | - | 6.46 | 1.01 | -2.93 |
| Other Operating Expenses | 3.79 | 12.18 | 5.18 | -8.70 | - |
| Otherunder Preferred Stock Dividend | - | 0 | 4.89 | 0 | 0 |
| Amortization | - | 0.70 | 0.76 | 0.76 | 0.44 |
| Amortization Of Intangibles Income Statement | - | 0.70 | 0.76 | 0.76 | 0.44 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MiMedx Group, Inc.this co. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| Rigel Pharmaceuticals, Inc. | RIGL | $560M | 1.52 | 1.43 | 93.8% | 4.35 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $560M |
| - |
| - |
| - |
| - |
| - |
| 23.30 |
| -2.14 |
| -9.2% |
| 9.00 |
| Cytek Biosciences, Inc. | CTKB | $559M | -8.40 | 1.64 | -19.5% | -28.29 |
| Cerus Corporation | CERS | $559M | - | 8.70 | -24.3% | - |
| NeuroPace, Inc. | NPCE | $556M | -25.92 | 29.24 | -112.8% | -50.21 |
| Fulgent Genetics, Inc. | FLGT | $554M | -9.15 | 0.50 | -5.4% | -11.16 |
| Peer Median | - | -6.45 | 2.08 | -14.3% | -6.43 | |
Historically, May has averaged the highest return (+13.5%); Sep the lowest (-18.9%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -24.5%Negative MonthJan 2026: -24.52% | -4.3%Negative MonthFeb 2026: -4.31% | -19.2%Negative MonthMar 2026: -19.22% | -14.9%Negative MonthApr 2026: -14.94% | +9.5%Positive MonthMay 2026: +9.52% | +4.6%Positive MonthJun 2026: +4.62% | +7.3%Positive MonthJul 2026: +7.27% | +7.7%*Positive MonthAug 2026: +7.75% | — | — | — | — |
| 2025 | -9.6%Negative MonthJan 2025: -9.56% | -3.4%Negative MonthFeb 2025: -3.45% | -9.5%Negative MonthMar 2025: -9.52% | -9.5%Negative MonthApr 2025: -9.47% | -6.5%Negative MonthMay 2025: -6.54% | -5.0%Negative MonthJun 2025: -4.98% | +17.7%Positive MonthJul 2025: +17.68% | -1.3%Neutral MonthAug 2025: -1.25% | -1.7%Neutral MonthSep 2025: -1.69% | +9.6%Positive MonthOct 2025: +9.60% | -10.1%Negative MonthNov 2025: -10.07% | -1.6%Neutral MonthDec 2025: -1.60% |
| 2024 | -11.7%Negative MonthJan 2024: -11.74% | +5.4%Positive MonthFeb 2024: +5.43% | -5.6%Negative MonthMar 2024: -5.64% | -20.0%Negative MonthApr 2024: -20.00% | +16.1%Positive MonthMay 2024: +16.07% | -3.1%Negative MonthJun 2024: -3.08% | +7.5%Positive MonthJul 2024: +7.50% | -8.2%Negative MonthAug 2024: -8.19% | -13.6%Negative MonthSep 2024: -13.60% | +15.9%Positive MonthOct 2024: +15.91% | +35.0%Positive MonthNov 2024: +35.04% | +4.0%Positive MonthDec 2024: +4.00% |
| 2023 | +39.2%Positive MonthJan 2023: +39.21% | +24.3%Positive MonthFeb 2023: +24.29% | -29.1%Negative MonthMar 2023: -29.11% | +12.3%Positive MonthApr 2023: +12.32% | +53.0%Positive MonthMay 2023: +53.00% | +12.8%Positive MonthJun 2023: +12.80% | +22.1%Positive MonthJul 2023: +22.09% | -8.1%Negative MonthAug 2023: -8.05% | -1.8%Neutral MonthSep 2023: -1.75% | -10.0%Negative MonthOct 2023: -10.01% | +18.4%Positive MonthNov 2023: +18.45% | +12.9%Positive MonthDec 2023: +12.87% |
| 2022 | -17.9%Negative MonthJan 2022: -17.88% | +1.8%Neutral MonthFeb 2022: +1.81% | -6.7%Negative MonthMar 2022: -6.73% | -16.1%Negative MonthApr 2022: -16.14% | -1.0%Neutral MonthMay 2022: -1.01% | -11.3%Negative MonthJun 2022: -11.25% | -1.4%Neutral MonthJul 2022: -1.44% | +3.2%Positive MonthAug 2022: +3.22% | -18.7%Negative MonthSep 2022: -18.70% | +3.1%Positive MonthOct 2022: +3.14% | +9.8%Positive MonthNov 2022: +9.80% | -14.5%Negative MonthDec 2022: -14.46% |
| 2021 | — | — | — | — | +10.2%Positive MonthMay 2021: +10.21% | +17.0%Positive MonthJun 2021: +17.03% | -2.0%Neutral MonthJul 2021: -2.00% | +20.4%Positive MonthAug 2021: +20.39% | -58.9%Negative MonthSep 2021: -58.94% | +13.0%Positive MonthOct 2021: +13.04% | +2.3%Positive MonthNov 2021: +2.34% | -13.8%Negative MonthDec 2021: -13.84% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
